Ratio Analysis: Unpacking Forte Biosciences Inc (FBRX)’s Price-to-Cash and Price-to-Free Cash Flow

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $0.39 in the prior trading day, Forte Biosciences Inc (NASDAQ: FBRX) closed at $0.31, down -20.51%. In other words, the price has decreased by -$20.51 from its previous closing price. On the day, 1.61 million shares were traded. FBRX stock price reached its highest trading level at $0.4267 during the session, while it also had its lowest trading level at $0.2796.

Ratios:

Our goal is to gain a better understanding of FBRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.82 and its Current Ratio is at 2.82. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

On September 20, 2021, Chardan Capital Markets Upgraded its rating to Buy which previously was Sell and also lowered its target price recommendation from $4 to $3.50.

Truist Downgraded its Buy to Hold on September 03, 2021, while the target price for the stock was maintained at $4.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 18 ’23 when Wagner Paul A. bought 10,000 shares for $0.75 per share. The transaction valued at 7,525 led to the insider holds 1,823,236 shares of the business.

Wagner Paul A. bought 10,520 shares of FBRX for $7,351 on Dec 13 ’23. The insider now owns 1,803,236 shares after completing the transaction at $0.70 per share. On Dec 14 ’23, another insider, Wagner Paul A., who serves as the insider of the company, bought 10,000 shares for $0.72 each. As a result, the insider paid 7,200 and bolstered with 1,813,236 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FBRX now has a Market Capitalization of 11316209 and an Enterprise Value of -16231472.

Stock Price History:

The Beta on a monthly basis for FBRX is 0.06, which has changed by -0.53125 over the last 52 weeks, in comparison to a change of 0.24841464 over the same period for the S&P500. Over the past 52 weeks, FBRX has reached a high of $0.91, while it has fallen to a 52-week low of $0.38. The 50-Day Moving Average of the stock is -41.79%, while the 200-Day Moving Average is calculated to be -50.18%.

Shares Statistics:

The stock has traded on average 21.21K shares per day over the past 3-months and 25600 shares per day over the last 10 days, according to various share statistics. A total of 36.34M shares are outstanding, with a floating share count of 32.49M. Insiders hold about 10.99% of the company’s shares, while institutions hold 55.58% stake in the company. Shares short for FBRX as of 1722384000 were 9098 with a Short Ratio of 0.43, compared to 1719532800 on 20321. Therefore, it implies a Short% of Shares Outstanding of 9098 and a Short% of Float of 0.029999999000000003.

Earnings Estimates

Forte Biosciences Inc (FBRX) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.08 and low estimates of -$0.17.

Analysts are recommending an EPS of between -$0.51 and -$0.66 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.54, with 3.0 analysts recommending between -$0.41 and -$0.68.

Most Popular